Parke-Davis/Ribozyme Pharmaceuticals agreement
Executive Summary
Collaboration announced April 21 will apply RPI's ribozyme technology to the treatment of osteoarthritis. The deal includes an equity investment in RPI by the Warner-Lambert division, as well as royalties and milestone payments to RPI. RPI will manufacture and the two companies will copromote in North America any products developed through the agreement. Boulder, Colo.-based RPI is currently developing ribozymes for HIV, herpes simplex virus and cardiovascular restenosis.